BIOCON PHARMA
GenericsBIOCON PHARMA is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Oncology.
BIOCON PHARMA at a Glance
- Fast trial execution (17 months median completion)
BIOCON PHARMA's Key Drugs
BIOCON PHARMA's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
BIOCON PHARMA's Recent FDA Approvals
BIOCON PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
BIOCON PHARMA's Therapeutic Areas
BIOCON PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIOCON PHARMA's Top Competitors
BIOCON PHARMA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIOCON PHARMA Pipeline Snapshot
Active clinical trials for BIOCON PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/3 completed
- • Speed: 17 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2006-12-20
- Latest
- 2026-04-28
- Applications
- 30
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges